Sapkota Lab Describes A ‘Protein Missile’ System To Destroy Endogenous Proteins In Cells

L-R: Luke Hutchinson and Luke Fulcher, Sapkota lab
L-R: Luke Hutchinson and Luke Fulcher, Sapkota lab

Being able to selectively and rapidly degrade target proteins in cells is desirable in research and therapeutics. This would overcome the limitations of traditional approaches, such as CRISPR/Cas9-mediated gene knockouts, which are irreversible and often not feasible for many essential proteins, and RNA interference, which necessitates prolonged treatments, can lead to incomplete knockdowns and is often associated with off-target effects. 

The Sapkota lab has engineered an Affinity-directed PROtein Missile (AdPROM) system for an efficient and rapid degradation of endogenous target proteins in many cells. The AdPROM system combines the Cullin2 E3 ligase machinery with high-affinity polypeptide binders, such as camelid nanobodies, of specific target proteins, to selectively recruit the target proteins for ubiquitin-mediated proteasomal degradation. 

The findings published in Open Biology describe the selective degradation of two proteins, namely SHP2 and ASC, through AdPROM. 

The work was spearheaded by two PhD students in the Sapkota lab, Luke Fulcher and Luke Hutchinson. Thomas Macartney from our cloning team at the Division of Signal Transduction Therapy was instrumental in designing and delivering all the AdPROM constructs. Craig Turnbull, a Dundee undergraduate student, also contributed.

Gopal Sapkota said, “This is an extremely exciting technology that has far reaching applications and implications for research and drug discovery. The AdPROM technology is quite simple to assemble and versatile for use in any cell. Basically, it requires an affinity probe that selectively recognizes the endogenous target protein of choice. With rapid advances in camelid nanobody and synthetic polypeptide technologies, it won’t be too long before we have access to affinity probes against pretty much any target protein.” 

He further added, “The exciting part is, even if no affinity probes against some target proteins exist, we can still employ AdPROM on any target protein by first modifying the target protein by CRISPR/Cas9 genome editing.”

Rapid degradation of target protein allows the scientists to assess the effect of their loss on cellular responses and reversal of disease states. The efficiency, versatility and simplicity of AdPROM allows anyone to rapidly test whether the degradation of specific target protein offers a viable therapeutic opportunity. In this way, decisions on the development of drugs, such as PROTACs, that induce degradation of specific target proteins can be made.

Professor Dario Alessi, the director of the MRC Protein Phosphorylation Unit, said, “This is very exciting new technology that will enable researchers to better understand the biological roles of proteins in cells. It has great potential to enable scientists to test ideas to generate improved drugs.”

If you think the AdPROM methodology helps your studies, please contact for reagents and advice.

Principal Investigator